NCT07203729招募中2 期
Trastuzumab Rezetecan (SHR-A1811) Versus Chemotherapy of Physician's Choice in Patients With HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis：A Randomized, Prospective, Open-Label Phase II Trial.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences1 个研究点 分布在 1 个国家目标入组 184 人开始时间: 2026年3月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 184
- 试验地点
- 1
- 主要终点
- Progression-Free Survival (PFS)
研究概览
简要总结
The goal of this clinical trial is to learn if Trastuzumab Rezetecan (SHR-A1811) is safe and tolerable for patients with HER2-Low unresectable/metastatic breast cancer complicated with visceral crisis. Participants will take Trastuzumab Rezetecan every three weeks, until disease progression or intolerable toxicity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Age: ≥18 years old and ≤75 years old;
- •Pathologically confirmed HER2-Low unresectable or metastatic breast cancer;
- •Visceral crisis is defined as severe organ dysfunction as assessed by signs, symptoms and laboratory studies, resulting from rapid progression of neoplastic disease and indicative of substantial visceral compromise that may serve as an indication for more aggressive therapeutic intervention, including：a）Liver visceral crisis: rapidly increasing bilirubin >1.5 × ULN in the absence of Gilbert's syndrome or biliary tract obstruction；b）Lung visceral crisis: rapidly increasing dyspnoea at rest, not alleviated by drainage of pleural effusion；c）Other visceral crises: the evaluation is conducted by the clinician based on the definition of visceral crisis specified in the ABC7 guideline.
- •Patients whom investigators deem to have indications for single-agent chemotherapy.
- •Sufficient bone marrow function, defined as follows：a) Neutrophil count (ANC) ≥ 1,500/mm³ (1.5 × 10⁹/L)；b) Platelet count (PLT) ≥ 80 ×10^9/L；c) Hemoglobin (Hb) ≥ 80 g/L；
- •Patients who have received ≤ 1 line of chemotherapy in the advanced stage are permitted.
- •Patients who have received endocrine therapy in the advanced stage are permitted.
- •Previous treatment with CDK4/6 inhibitors is permitted.
- •Previous or concurrent local treatment for symptom relief is permitted.
- •For female subjects who are premenopausal or not surgically sterilized:
- •A serum pregnancy test must be performed within 7 days before the first dose of study drug, with a negative result. They must agree to either abstain from sexual activity or use a medically approved highly effective contraceptive method from the time of signing the informed consent form, throughout the study period, and for 1 year after the last dose of study drug.
- •Patients must voluntarily participate in this study, sign the informed consent form, have good compliance, and be willing to cooperate with follow-up.
排除标准
- •Have received treatment with new antibody-drug conjugates (ADCs) at any stage of breast cancer.
- •Are deemed by the investigator as unsuitable for systemic chemotherapy.
- •Have had other malignant tumors within the past 5 years, excluding cured carcinoma in situ of the cervix, cutaneous basal cell carcinoma, or cutaneous squamous cell carcinoma (patients with other malignant tumors that occurred more than 5 years before randomization and were cured solely by surgery are eligible for enrollment).
- •Have undergone major surgical procedures or suffered significant trauma within 4 weeks prior to randomization, or are expected to undergo major surgical treatment.
- •Have severe heart disease or cardiac discomfort, including but not limited to the following conditions：a) A history of heart failure or systolic dysfunction (left ventricular ejection fraction [LVEF] < 50%)；b) High-risk angina pectoris requiring treatment or cardiac arrhythmias；c) Clinically significant valvular heart disease；d) ECG findings indicating transmural myocardial infarction；e) Poorly controlled hypertension.
- •Have a known history of allergy to any component of the drugs in this protocol.
- •Have a history of immunodeficiency, including HIV infection, or other acquired or congenital immunodeficiency diseases.
- •Have a known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
- •Have a known history of psychotropic substance abuse or drug addiction.
- •Are pregnant or lactating women, or women of childbearing age who are unwilling to use effective contraceptive measures throughout the trial period and within 7 months after the last administration of the study drug.
- •Have severe diseases, other comorbidities that would interfere with the planned treatment, or any other conditions that make them unsuitable for participation in this study (e.g., active hepatitis B, pulmonary infection requiring treatment).
研究组 & 干预措施
Arm 1：Trastuzumab Rezetecan
Experimental
干预措施: Trastuzumab Rezetecan (Drug)
Arm 2：Chemotherapy of Physician's Choice
Active Comparator
干预措施: Chemotherapy of Physician's Choice (Drug)
结局指标
主要结局
Progression-Free Survival (PFS)
时间窗: From the start of treatment to 36 month
Progression-Free Survival is defined as the time from randomization to first documented disease progression (PD) using Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) or death from any cause, whichever occurred first. The PFS will be will be estimated using Kaplan-Meier method. A Kaplan-Meier curve, median PFS, hazard ratio with appropriate confidence intervals will be reported.
次要结局
- Objective Overall Response Rate (ORR)(From the start of treatment to 36 month)
- Overall Survival (OS)(From the start of treatment to 36 month)
- Adverse events (AEs)(From the start of treatment to 36 month)
- Clinical Benefit Response (CBR)(From the start of treatment to 36 month)
研究者
Ma Fei，MD
Chief Physician
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
研究点 (1)
Loading locations...
相似试验
招募中
2 期
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BCBreast Cancer Early Stage Breast Cancer (Stage 1-3)NCT06927180Henan Cancer Hospital180
已完成
3 期
Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast CancerStage IV Breast CancerBreast CancerNCT00146549Dana-Farber Cancer Institute250
进行中（未招募）
3 期
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast CancerAdvanced or Metastatic Breast CancerNCT04494425AstraZeneca866
进行中（未招募）
3 期
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast CancerHER2-PositiveRecurrent or Metastatic Breast CancerNCT06057610Jiangsu HengRui Medicine Co., Ltd.868
招募中
1 期
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)Colorectal CancerBiliary Tract CancerPancreatic Ductal AdenocarcinomaNCT06428409Merck Sharp & Dohme LLC220